Seroquel XR MDD indication given CHMP nod
This article was originally published in Scrip
Executive Summary
The EU's CHMP has endorsed AstraZeneca's atypical antipsychotic Seroquel XR (quetiapine fumarate extended-release) as an add-on to ongoing treatment for major depressive episodes in patients with major depressive disorder who have had sub-optimal response to treatment with other antidepressants.